BioMarin Pharmaceuticals BMRN Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| ALDURAZYME | $36.74M-25.0% | $49.39M+26.5% | $53.71M-24.4% | $56.44M+46.4% | $48.98M+38.9% | |
| BRINEURA | $47.1M+16.7% | $49.39M+3.5% | $47.95M+29.6% | $48.69M+7.5% | $40.36M+3.4% | |
| KUVAN | $23.88M-5.0% | $23.34M-17.6% | $24.03M-14.5% | $27.03M-5.3% | $25.14M-30.0% | |
| NAGLAZYME | $130.07M+13.8% | $120.22M+9.3% | $122.03M-7.5% | $128.87M-2.4% | $114.29M+8.2% | |
| PALYNZIQ | $89.56M-4.0% | $125.33M+24.8% | $108.78M+20.0% | $105.94M+20.0% | $93.27M+23.2% | |
| ROCTAVIAN | $2.64M-74.9% | $12.75M+20.9% | $3.18M-56.0% | $9.2M+23.8% | $10.51M+1,138% | |
| Royalty and other revenues | $6.13M-41.6% | $15.24M+30.5% | $15.32M+29.0% | $12.43M+25.5% | $10.5M-4.7% | |
| VIMIZIM | $210.2M+11.6% | $205.53M+7.6% | $182.76M+2.6% | $215.42M+21.0% | $188.35M-2.2% | |
| VOXZOGO | $219.88M+2.9% | $273.39M+31.1% | $218.39M+15.1% | $221.39M+20.4% | $213.75M+39.8% | |
| R&D by Product | ||||||
| Later-stage clinical programs | $36.18M+153% | $29.26M+199% | $251.65M+2,397% | $13.13M+70.2% | $14.29M-83.1% | |
| Marketed products | $55.33M+2.5% | $59.61M-2.4% | $64.11M-8.3% | $52.21M-25.4% | $53.97M-36.2% | |
| Research and early pipeline | $87.29M-3.5% | $103.55M+0.9% | $93.72M-10.7% | $95.97M-9.5% | $90.47M-24.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does BioMarin Pharmaceuticals break its business down?
- BioMarin Pharmaceuticals (BMRN) reports total revenues by product across 9 parts — ALDURAZYME, BRINEURA, KUVAN, NAGLAZYME and PALYNZIQ. Each is extracted from the segment footnotes and tracked over time.
- Where does BioMarin Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in BioMarin Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
